Profound MedicalPROF -1.16%73 PS Ratio is 12.25 as of Jul. 07, 2026, which is 53% below its 10-year median of 26.33. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 805 Medical Devices & Instruments companies, Profound Medical ranks worse than 86.71% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Profound Medical's share price is $7.25.
Profound Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.59. Hence, Profound Medical's PS Ratio for today is 12.25.
The historical rank and industry rank for Profound Medical's PS Ratio or its related term are showing as below:
PROF'
s PS Ratio Range Over the Past 10 Years
Min: 9.05 Med: 26.33 Max: 94.39
Current: 12.69
During the past 12 years, Profound Medical's highest PS Ratio was 94.39. The lowest was 9.05. And the median was 26.33.
PROF's PS Ratio is ranked worse than 86.71% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs PROF: 12.69
During the past 12 months, the average Revenue per Share Growth Rate of Profound Medical was 28.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.90% per year.
During the past 12 years, Profound Medical's highest 3-Year average Revenue per Share Growth Rate was 19.00% per year. The lowest was -12.60% per year. And the median was 4.25% per year.
Back to Basics: PS Ratio
Profound Medical (NAS:PROF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Profound Medical PS Ratio Related Terms
Profound Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Profound Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Profound Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Profound Medical's Share Price of today is $7.25. Profound Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Profound Medical (PROF) has a PS Ratio of 12.25 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Profound Medical and its competitors. This is 53% below median its historical median of 26.33. Over the past decade, Profound Medical's PS Ratio has ranged from 9.05 to 94.39. According to the industry distribution chart, Profound Medical ranks #698 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 86.7%.
Is Profound Medical's PS Ratio too high?
Profound Medical's current PS Ratio of 12.25 is 53% below median its 10-year median of 26.33. Over the past 10 years, this metric has ranged from a low of 9.05 to a high of 94.39. The Medical Devices & Instruments industry median PS Ratio is 2.94. Profound Medical's value of 12.25 is 316.7% above this industry median. Based on the distribution chart, Profound Medical ranks #698 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #698 out of 805 companies for PS Ratio. This places Profound Medical in the lower half of its industry. The industry median PS Ratio is 2.94. Profound Medical's value of 12.25 is 316.7% above this benchmark. Historically, Profound Medical's own PS Ratio has ranged from 9.05 to 94.39 over the past decade. While the company's 10-year median is 26.33 vs. the industry median of 2.94, Profound Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current PS Ratio of 12.25 is 316.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current PS Ratio is 12.25, which is 53% below median its own 10-year median of 26.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.25 — trading 49.2% below its estimated fair value. The current PS Ratio is 12.25, which is 53% below median its 10-year median of 26.33 and 316.7% above the Medical Devices & Instruments industry median of 2.94. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Profound Medical (PROF), the current PS Ratio is 12.25 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.25 is trading 49.2% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
PS Ratio: 12.25 (53% below median its 10-year median of 26.33)
GF Value™: $14.28 vs. price of $7.25 (49.2% below fair value)
Industry Position: 316.7% above the Medical Devices & Instruments median (#698 of 805)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
